|
1
|
Stingl J and Caldas C: Molecular
heterogeneity of breast carcinomas and the cancer stem cell
hypothesis. Nat Rev Cancer. 7:791–799. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lobo NA, Shimono Y, Qian D and Clarke MF:
The biology of cancer stem cells. Annu Rev Cell Dev Biol.
23:675–699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel SA, Ndabahaliye A, Lim PK, Milton R
and Rameshwar P: Challenges in the development of future treatments
for breast cancer stem cells. Breast Cancer (Dove Med Press).
2:1–11. 2010.PubMed/NCBI
|
|
5
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Veronesi U, De Palo G, Costa A, Formelli
F, Marubini E and Del Vecchio M: Chemoprevention of breast cancer
with retinoids. J Natl Cancer Inst Monogr. 12:93–97.
1992.PubMed/NCBI
|
|
7
|
Fisher B, Costantino JP, Wickerham DL,
Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N,
Atkins J, et al: Tamoxifen for prevention of breast cancer: Report
of the National Surgical Adjuvant Breast and Bowel Project P-1
Study. J Natl Cancer Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: Therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential Paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Phuc P, Nhan PL, Nhung TH, Tam NT,
Hoang NM, Tue VG, Thuy DT and Ngoc PK: Downregulation of CD44
reduces doxorubicin resistance of CD44CD24 breast cancer cells.
Onco Targets Ther. 4:71–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang F, Song C, Ma Y, Tang L, Xu Y and
Wang H: Effect of fibroblasts on breast cancer cell mammosphere
formation and regulation of stem cell-related gene expression. Int
J Mol Med. 28:365–371. 2011.PubMed/NCBI
|
|
13
|
Suto A, Bradlow HL, Kubota T, Kitajima M,
Wong GY, Osborne MP and Telang NT: Alteration in proliferative and
endocrine responsiveness of human mammary carcinoma cells by
prototypic tumor-suppressing agents. Steroids. 58:215–219. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Telang NT, Katdare M, Bradlow HL, Osborne
MP and Fishman J: Inhibition of proliferation and modulation of
estradiol metabolism: Novel mechanisms for breast cancer prevention
by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med.
216:246–252. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jinno H, Steiner MG, Nason-Burchenal K,
Osborne MP and Telang NT: Preventive efficacy of receptor class
selective retinoids on HER-2/neu oncogene expressing preneoplastic
human mammary epithelial cells. Int J Oncol. 21:127–134.
2002.PubMed/NCBI
|
|
16
|
Mukherjee B, Telang N and Wong GYC: Growth
inhibition of estrogen receptor positive human breast cancer cells
by Taheebo from the inner bark of Tabebuia avellandae tree. Int J
Mol Med. 24:253–260. 2009.PubMed/NCBI
|
|
17
|
Telang N and Katdare M: Epithelial cell
culture models for the prevention and therapy of clinical breast
cancer (Review). Oncol Lett. 3:744–750. 2012.PubMed/NCBI
|
|
18
|
Telang N, Li G, Sepkovic D, Bradlow HL and
Wong GY: Comparative efficacy of extracts from Lycium barbarum bark
and fruit on estrogen receptor positive human mammary carcinoma
MCF-7 cells. Nutr Cancer. 66:278–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Telang N: Cellular metabolism of estradiol
in models for select molecular subtypes of clinical breast cancer.
J Steroids Hormon Sci. 5:1–5. 2014. View Article : Google Scholar
|
|
20
|
Telang NT, Li G, Sepkovic DW, Bradlow HL
and Wong GY: Anti-proliferative effects of Chinese herb Cornus
officinalis in a cell culture model for estrogen receptor-positive
clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI
|
|
21
|
National Comprehensive Cancer Network:
NCCN Clinical practice guidelines in oncology: Breast Cancer.
1(2010)http://www.nccn.org2010.Accessed.
July 05–2011
|
|
22
|
Johnston SRD and Dowsett M: Aromatase
inhibitors for breast cancer: Lessons from the laboratory. Nat Rev
Cancer. 3:821–831. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER-2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ibrahim YH, García-García C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martin HL, Smith L and Tomlinson DC:
Multidrug-resistant breast cancer: Current perspectives. Breast
Cancer (Dove Med Press). 6:1–13. 2014.PubMed/NCBI
|
|
27
|
Hoffmeyer K, Raggioli A, Rudloff S, Anton
R, Hierholzer A, Del Valle I, Hein K, Vogt R and Kemler R:
Wnt/β-catenin signaling regulates telomerase in stem cells and
cancer cells. Science. 336:1549–1554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ,
Lee ES, Park JH, Yun CH, Chung JU, Lee KJ, et al: Wnt/β-catenin
small molecule inhibitor CWP232228 preferentially inhibits the
growth of breast cancer stem-like cells. Cancer Res. 75:1961–1702.
2015. View Article : Google Scholar
|
